The FDA granted AstraZeneca’s Alexion Pharmaceuticals orphan status for selumetinib, its treatment of malignant glioma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca launches health-tech business Evinova
- AstraZeneca (NASDAQ:AZN) Unveils New AI-Driven Health Solutions Unit
- AstraZeneca announces launch of Evinova, a digital health solutions provider
- AstraZeneca announces approval of Truqap plus Faslodex in the U.S.
- AstraZeneca reports Imfinzi plus chemotherapy approved in China for BTC